-
Je něco špatně v tomto záznamu ?
Prevention and reversal of obesity and glucose intolerance in mice by DHA derivatives
M. Rossmeisl, T. Jeleník, Z. Jílková, K. Slámová, V. Kus, M. Hensler, D. Medříková, C. Povýšil, P. Flachs, V. Mohamed-Ali, M. Bryhn, K. Berge, A.K. Holmeide, J. Kopecký
Jazyk angličtina Země Spojené státy americké
Typ dokumentu práce podpořená grantem
NLK
Free Medical Journals
od 1993 do 2017
ProQuest Central
od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2000-01-01 do Před 1 rokem
Family Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest)
od 2000-01-01 do Před 1 rokem
Wiley Free Content
od 2006 do Před 1 rokem
- MeSH
- dietní tuky MeSH
- energetický příjem MeSH
- glukosa metabolismus MeSH
- glukózový toleranční test MeSH
- hmotnostní přírůstek MeSH
- hypolipidemika terapeutické užití MeSH
- kyseliny dokosahexaenové terapeutické užití MeSH
- modely nemocí na zvířatech MeSH
- myši inbrední C57BL MeSH
- myši MeSH
- obezita farmakoterapie prevence a kontrola MeSH
- polymerázová řetězová reakce MeSH
- porucha glukózové tolerance farmakoterapie prevence a kontrola MeSH
- RNA genetika izolace a purifikace MeSH
- triglyceridy metabolismus MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- práce podpořená grantem MeSH
The n-3 polyunsaturated fatty acids, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), exert hypolipidemic effects and prevent development of obesity and insulin resistance in animals fed high-fat diets. We sought to determine the efficacy of alpha-substituted DHA derivatives as lipid-lowering, antiobesity, and antidiabetic agents. C57BL/6 mice were given a corn oil-based high-fat (35% weight/weight) diet (cHF), or cHF with 1.5% of lipids replaced with alpha-methyl DHA ethyl ester (Substance 1), alpha-ethyl DHA ethyl ester (Substance 2), alpha,alpha-di-methyl DHA ethyl ester (Substance 3), or alpha-thioethyl DHA ethyl ester (Substance 4) for 4 months. Plasma markers of glucose and lipid metabolism, glucose tolerance, morphology, tissue lipid content, and gene regulation were characterized. The cHF induced obesity, hyperlipidemia, impairment of glucose homeostasis, and adipose tissue inflammation. Except for Substance 3, all other substances prevented weight gain and Substance 2 exerted the strongest effect (63% of cHF-controls). Glucose intolerance was significantly prevented (~67% of cHF) by both Substance 1 and Substance 2. Moreover, Substance 2 lowered fasting glycemia, plasma insulin, triacylglycerols, and nonesterified fatty acids (73, 9, 47, and 81% of cHF-controls, respectively). Substance 2 reduced accumulation of lipids in liver and skeletal muscle, as well as adipose tissue inflammation associated with obesity. Substance 2 also induced weight loss in dietary obese mice. In contrast to DHA administered either alone or as a component of the EPA/DHA concentrate (replacing 15% of dietary lipids), Substance 2 also reversed established glucose intolerance in obese mice. Thus, Substance 2 represents a novel compound with a promising potential in the treatment of obesity and associated metabolic disturbances.
- 000
- 04059naa 2200601 a 4500
- 001
- bmc11017215
- 003
- CZ-PrNML
- 005
- 20130617125736.0
- 008
- 110629s2009 xxu e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Rossmeisl, Martin. $7 xx0270807
- 245 10
- $a Prevention and reversal of obesity and glucose intolerance in mice by DHA derivatives / $c M. Rossmeisl, T. Jeleník, Z. Jílková, K. Slámová, V. Kus, M. Hensler, D. Medříková, C. Povýšil, P. Flachs, V. Mohamed-Ali, M. Bryhn, K. Berge, A.K. Holmeide, J. Kopecký
- 314 __
- $a Department of Adipose Tissue Biology and Center for Applied Genomics, Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
- 520 9_
- $a The n-3 polyunsaturated fatty acids, especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), exert hypolipidemic effects and prevent development of obesity and insulin resistance in animals fed high-fat diets. We sought to determine the efficacy of alpha-substituted DHA derivatives as lipid-lowering, antiobesity, and antidiabetic agents. C57BL/6 mice were given a corn oil-based high-fat (35% weight/weight) diet (cHF), or cHF with 1.5% of lipids replaced with alpha-methyl DHA ethyl ester (Substance 1), alpha-ethyl DHA ethyl ester (Substance 2), alpha,alpha-di-methyl DHA ethyl ester (Substance 3), or alpha-thioethyl DHA ethyl ester (Substance 4) for 4 months. Plasma markers of glucose and lipid metabolism, glucose tolerance, morphology, tissue lipid content, and gene regulation were characterized. The cHF induced obesity, hyperlipidemia, impairment of glucose homeostasis, and adipose tissue inflammation. Except for Substance 3, all other substances prevented weight gain and Substance 2 exerted the strongest effect (63% of cHF-controls). Glucose intolerance was significantly prevented (~67% of cHF) by both Substance 1 and Substance 2. Moreover, Substance 2 lowered fasting glycemia, plasma insulin, triacylglycerols, and nonesterified fatty acids (73, 9, 47, and 81% of cHF-controls, respectively). Substance 2 reduced accumulation of lipids in liver and skeletal muscle, as well as adipose tissue inflammation associated with obesity. Substance 2 also induced weight loss in dietary obese mice. In contrast to DHA administered either alone or as a component of the EPA/DHA concentrate (replacing 15% of dietary lipids), Substance 2 also reversed established glucose intolerance in obese mice. Thus, Substance 2 represents a novel compound with a promising potential in the treatment of obesity and associated metabolic disturbances.
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a dietní tuky $7 D004041
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a kyseliny dokosahexaenové $x terapeutické užití $7 D004281
- 650 _2
- $a energetický příjem $7 D002149
- 650 _2
- $a glukosa $x metabolismus $7 D005947
- 650 _2
- $a porucha glukózové tolerance $x farmakoterapie $x prevence a kontrola $7 D018149
- 650 _2
- $a glukózový toleranční test $7 D005951
- 650 _2
- $a hypolipidemika $x terapeutické užití $7 D000960
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a obezita $x farmakoterapie $x prevence a kontrola $7 D009765
- 650 _2
- $a polymerázová řetězová reakce $7 D016133
- 650 _2
- $a RNA $x genetika $x izolace a purifikace $7 D012313
- 650 _2
- $a triglyceridy $x metabolismus $7 D014280
- 650 _2
- $a hmotnostní přírůstek $7 D015430
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1#
- $a Jeleník, Tomáš. $7 xx0300617
- 700 1_
- $a Macek Jílková, Zuzana, $d 1981- $7 xx0128795
- 700 1_
- $a Slámová, Kristýna $7 xx0125284
- 700 1#
- $a Kus, Vladimír. $7 _AN051187
- 700 1#
- $a Hensler, Michal. $7 _AN044964
- 700 1_
- $a Medříková, Dáša $7 xx0105138
- 700 1_
- $a Povýšil, Ctibor, $d 1943- $7 jn20001103579
- 700 1#
- $a Flachs, Pavel. $7 _AN029338
- 700 1_
- $a Mohamed-Ali, Vidya
- 700 1_
- $a Bryhn, Morten
- 700 1_
- $a Berge, Kjetil
- 700 1_
- $a Holmeide, Anne K.
- 700 1_
- $a Kopecký, Jan, $d 1951- $7 jo20010086901
- 773 0_
- $t Obesity $w MED00150944 $g Roč. 17, č. 5 (2009), s. 1023-1031 $x 1930-7381
- 910 __
- $a ABA008 $b x $y 2
- 990 __
- $a 20110720103247 $b ABA008
- 991 __
- $a 20130617130123 $b ABA008
- 999 __
- $a ok $b bmc $g 864200 $s 727013
- BAS __
- $a 3
- BMC __
- $a 2009 $x MED00150944 $b 17 $c 5 $d 1023-1031 $i 1930-7381 $m Obesity $n Obesity (Silver Spring)
- LZP __
- $a 2011-3B09/BBjvme